CA1338831C - 4-thiazolidine-carboxylic acid derivatives - Google Patents
4-thiazolidine-carboxylic acid derivativesInfo
- Publication number
- CA1338831C CA1338831C CA000571593A CA571593A CA1338831C CA 1338831 C CA1338831 C CA 1338831C CA 000571593 A CA000571593 A CA 000571593A CA 571593 A CA571593 A CA 571593A CA 1338831 C CA1338831 C CA 1338831C
- Authority
- CA
- Canada
- Prior art keywords
- thiazolidine
- carboxylic acid
- compound
- formula
- alkali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical class OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 title description 5
- 239000003513 alkali Substances 0.000 claims abstract description 4
- XBJWOGLKABXFJE-UHFFFAOYSA-N 3-ethoxycarbonyl-1,3-thiazolidine-4-carboxylic acid Chemical compound CCOC(=O)N1CSCC1C(O)=O XBJWOGLKABXFJE-UHFFFAOYSA-N 0.000 claims abstract description 3
- -1 amino acid salts Chemical class 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000003097 mucus Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims 2
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims 2
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 claims 2
- MDCAEYBLHBHSOT-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;3-ethoxycarbonyl-1,3-thiazolidine-4-carboxylic acid Chemical compound NCCCC[C@H](N)C(O)=O.CCOC(=O)N1CSCC1C(O)=O MDCAEYBLHBHSOT-ZSCHJXSPSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 108010067372 Pancreatic elastase Proteins 0.000 description 8
- 102000016387 Pancreatic elastase Human genes 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 206010014561 Emphysema Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000002849 elastaseinhibitory effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229950001139 timonacic Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 102100035371 Chymotrypsin-like elastase family member 1 Human genes 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101000737684 Homo sapiens Chymotrypsin-like elastase family member 1 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000786363 Rhampholeon spectrum Species 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- YBCQPYAIFHHIKE-UHFFFAOYSA-N ethyl n-(1,1-dioxo-2,3-dihydrothiophen-3-yl)carbamate Chemical compound CCOC(=O)NC1CS(=O)(=O)C=C1 YBCQPYAIFHHIKE-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE88110327T DE3869772D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-06-29 | 1988-06-29 | |
| EP88110327A EP0348541B1 (en) | 1988-06-29 | 1988-06-29 | N-carbethoxy-4-thiazolidine-carboxylic acid, process for its preparation and its use as medicament |
| ES198888110327T ES2034041T3 (es) | 1988-06-29 | 1988-06-29 | Acido n-carbotoxi-4-tiazolidin-carboxilico, proceso para su preparacion y su uso como medicamento. |
| AT88110327T ATE74354T1 (de) | 1988-06-29 | 1988-06-29 | N-karbethoxy-4-thiazolin-karbonsaeure, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. |
| CA000571593A CA1338831C (en) | 1988-06-29 | 1988-07-08 | 4-thiazolidine-carboxylic acid derivatives |
| US07/217,384 US4874776A (en) | 1988-06-29 | 1988-07-11 | Compound having mucus regulating and elastase-inhibitory activities, for the therapy of pulmonal emphysema and pulmonal fibrosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP88110327A EP0348541B1 (en) | 1988-06-29 | 1988-06-29 | N-carbethoxy-4-thiazolidine-carboxylic acid, process for its preparation and its use as medicament |
| CA000571593A CA1338831C (en) | 1988-06-29 | 1988-07-08 | 4-thiazolidine-carboxylic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1338831C true CA1338831C (en) | 1997-01-07 |
Family
ID=72039718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000571593A Expired - Fee Related CA1338831C (en) | 1988-06-29 | 1988-07-08 | 4-thiazolidine-carboxylic acid derivatives |
Country Status (6)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1245712B (it) * | 1991-04-09 | 1994-10-14 | Boehringer Mannheim Italia | Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree |
| ITMI20031941A1 (it) * | 2003-10-09 | 2005-04-10 | Sinclair Pharmaceuticals Ltd | Composizioni farmaceutiche topiche per il trattamento delle dermatiti |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR7420M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1968-04-24 | 1969-11-12 | ||
| FR8266M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1968-12-31 | 1970-10-26 | ||
| FR2204411B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1972-11-02 | 1976-03-05 | Claude Dufour | |
| IT1049444B (it) * | 1975-06-24 | 1981-01-20 | Italchemi Spa | Procedimento di preparazione ed applicazioni terapeutiche dell acido n p.clorofenossi isobutiroil tiazoli dincarbossilico |
| US4374249A (en) * | 1980-12-23 | 1983-02-15 | American Cyanamid Company | [4R]-3-(ω-Aroylpropionyl)-4-thiazolidinecarboxylic acids and esters |
| IT1190945B (it) * | 1982-08-06 | 1988-02-24 | Salus Research Sarm Spa | Composto ad azione broncosegretogoga,fluidificante ed antitussigena,procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono |
| EP0115091A1 (en) * | 1983-01-27 | 1984-08-08 | ENI-Ente Nazionale Idrocarburi | N-carboxyacyl derivatives of cyclic amino acids, useful as antihypertensives |
-
1988
- 1988-06-29 ES ES198888110327T patent/ES2034041T3/es not_active Expired - Lifetime
- 1988-06-29 AT AT88110327T patent/ATE74354T1/de not_active IP Right Cessation
- 1988-06-29 EP EP88110327A patent/EP0348541B1/en not_active Expired - Lifetime
- 1988-06-29 DE DE88110327T patent/DE3869772D1/de not_active Expired - Lifetime
- 1988-07-08 CA CA000571593A patent/CA1338831C/en not_active Expired - Fee Related
- 1988-07-11 US US07/217,384 patent/US4874776A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE74354T1 (de) | 1992-04-15 |
| DE3869772D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-05-07 |
| ES2034041T3 (es) | 1993-04-01 |
| EP0348541A1 (en) | 1990-01-03 |
| US4874776A (en) | 1989-10-17 |
| EP0348541B1 (en) | 1992-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0025692B1 (en) | Quinone derivatives, their production and use | |
| IE47798B1 (en) | Substituted ortho-anisamides,methods of preparing them,compositions containing them and their application as psychotropic agents | |
| EP0524553A1 (en) | Acylmercaptoalkanoyldipeptides, methods of preparation and their therapeutic use | |
| JPS5912650B2 (ja) | フエニル脂肪族飽和カルボン酸の塩類の製造法 | |
| US4426391A (en) | [(Alkoxycarbonyl)oxy]alkyl esters of methyldopa | |
| EP0480071B1 (en) | S-(lower fatty acid)-substituted glutathione derivative | |
| KR19980701869A (ko) | 사람 백혈구 엘라스타제 억제제로 유용한 프롤린 유도체 | |
| CN111635309B (zh) | 一种新型解热镇痛药物及其制备方法和用途 | |
| IE54896B1 (en) | Pyrrolacetic amides having antiinflammatory activity | |
| JPS6229566A (ja) | 新規グアニジノメチル安息香酸誘導体 | |
| JPH0788352B2 (ja) | ヒドロキシアルキルシステイン誘導体およびこれを含有する去痰剤 | |
| JPH03112933A (ja) | 抗腫瘍剤 | |
| EP0198542B1 (en) | Pharmaceutical compositions having therapeutical activity based on mercaptoethansulphonic acid, organic saline derivatives of the mercaptoethansulphonic acid useful for these compositions, and related process for their preparation | |
| CA1338831C (en) | 4-thiazolidine-carboxylic acid derivatives | |
| CA1167864A (en) | Esters of mercapto acyl-carnitines, process for their preparation and pharmaceutical compositions containing same | |
| EP0143399B1 (en) | Cysteine derivatives, a process for their preparation, and pharmaceutical compostions which contain them | |
| EP0218356B1 (en) | Phenylalanine derivatives and uses thereof | |
| JPS5940400B2 (ja) | 新規ｄ−アロ−ス誘導体及びこれを有効成分とする抗腫瘍剤 | |
| JPS5899490A (ja) | リン酸アミド誘導体およびその製造方法ならびにそれを含有する医薬 | |
| JP2700473B2 (ja) | ４−チアゾリン−カルボン酸誘導体、その製造法、並びに気管支分泌促進用および肝臓保護用製薬組成物 | |
| EP0096013B1 (en) | Salts of erythromycin showing a combined therapeutic activity, process for their preparation and pharmaceutical formulations containing them | |
| US4472424A (en) | Esters of 2-thenoylmercaptopropionylglycine with substituted hydroxybenzenes, process for their preparation and pharmaceutical compositions containing same | |
| BE885263A (fr) | Derives d'acides cyclohexane-carboxyliques | |
| JPH0144169B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP0177728B1 (en) | Arphamenine derivatives, a process for their preparation and their use as medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |